Research programme: anti-inflammatory antibodies - NovImmune/Tiziana

Drug Profile

Research programme: anti-inflammatory antibodies - NovImmune/Tiziana

Alternative Names: NI-1201; NI-1201/α-IL-6Rc; TZLS-501

Latest Information Update: 11 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovImmune SA
  • Developer Tiziana Life Sciences
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 07 Jun 2018 Preclinical development is ongoing in United Kingdom
  • 03 Jan 2017 Tiziana Life Sciences in-licenses NI 1201 from Novimmune
  • 28 Nov 2012 A compound from this programme (NI 0101) was advanced into clinical development [see separate profile]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top